Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06782360 · ClinicalTrials.gov registry record · NA

Cognitive Augmentation Via Multimodal Sensing and Auricular Neurostimulation

A NA study of Healthy and Cognitive Change, sponsored by OpenBCI.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT06782360: Recruiting NA study of Healthy and Cognitive Change, sponsored by OpenBCI.

NCT06782360 is a NA study of Healthy and Cognitive Change that is actively recruiting participants, run by OpenBCI. The registered enrollment target is 50 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06782360, a NA study of Healthy and Cognitive Change, is actively recruiting participants, sponsored by OpenBCI.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to extend this period of optimal cognitive performance by applying neurostimulation to buffer health volunteers against the effects of increased levels of stress, distraction, and cybersickness. The main questions it aims to answer are: * Can we use OpenBCI's head-mounted Galea biosensor + eXtended Reality (XR) platform to measure participants' cognitive state in relation to stress, attention and cybersickness? * How does applying external neurostimulation via Spark Biomedical's Sparrow Link transcutaneous auricular neurostimulation (tAN) system enhance cognitive performance with a closed-loop interface that automatically applies neurostimulation as a function of physiologically determined stress, attention, and cybersickness metrics? Researchers will compare the active neurostimulation group to the sham neurostimulation group to see if cognitive performance is improved with stimulation. Participants will complete 4 virtual reality tasks in the lab: * 2 tasks related to attention - Flanker and Gradual-onset Continual Performance Task (GradCPT) * The Multi-Attribute Task Battery (MATB) * A cybersickness task * And a baseline session before each task * Neurostimulation intervention will occur in response to cognitive states

Primary Outcome

Performance will be measured by number of correct responses and reaction time. Specially we will look at mean change in score (percentage of correct responses) and reduction in reaction time.

Interventions

  • DEVICE Active Neurostimulation
  • DEVICE Sham Stimulation

Study Locations (1)

New York

  • OpenBCI - Brooklyn

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-04-30
Est. Completion 2025-12
Phase NA
OpenBCI

1 total trials

What NCT06782360 shows while recruiting

NCT06782360 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower).

The record links to 3 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Active Neurostimulation is the first listed.

NCT06782360 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06782360 about?

NCT06782360 is a clinical study titled "Cognitive Augmentation Via Multimodal Sensing and Auricular Neurostimulation". The goal of this clinical trial is to extend this period of optimal cognitive performance by applying neurostimulation to buffer health volunteers against the effects of increased levels of stress, distraction, and cybersickness. The main questions it aims to answer are: * Can we use OpenBCI's head...

What is the current status of trial NCT06782360?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-04-30. Estimated completion is 2025-12.

What conditions does trial NCT06782360 study?

This clinical trial studies the following conditions: Healthy, Cognitive Change, Effects of External Neurostimulation on Cognition.

What interventions are being tested in trial NCT06782360?

The interventions under investigation include: Active Neurostimulation (DEVICE), Sham Stimulation (DEVICE).

Who is sponsoring clinical trial NCT06782360?

This trial is sponsored by OpenBCI, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06782360 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06782360's enrollment target sits among peer trials

50 448th of 1090 higher than 618 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

  • NCT01746836 · 50 participants · Phase 2

    Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06782360, the US trial registry maintained by the National Library of Medicine. NCT06782360 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.